PSMA is a type II transmembrane glycoprotein that is consistently overexpressed in over 90% of PCa cases, particularly in advanced and metastatic stages, making it a prime target for imaging and therapy [80, 81]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.